Cancer stem cell biomarkers and related signalling pathways

J Drug Target. 2024 Dec;32(1):33-44. doi: 10.1080/1061186X.2023.2295222. Epub 2024 Jan 12.

Abstract

Cancer stem cells (CSCs) represent a distinct subset of neoplastic cells characterised by their heightened capacity for tumorigenesis. These cells are implicated in the facilitation of cancer metastasis, recurrence, and resistance to conventional therapeutic interventions. Extensive scientific research has been devoted to the identification of biomarkers and the elucidation of molecular mechanisms in order to improve targeted therapeutic approaches. Accurate identification of cancer stem cells based on biomarkers can provide a theoretical basis for drug combinations of malignant tumours. Targeted biomarker-based therapies also offer a silver lining for patients with advanced malignancies. This review aims comprehensively to consolidate the latest findings on CSCs biomarkers, targeted agents as well as biomarkers associated signalling pathways in well-established cancer types, thereby contributing to improved prognostic outcomes.

Keywords: Cancer stem cell; biomarker; signaling pathway; targeting agents.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Biomarkers / metabolism
  • Biomarkers, Tumor / metabolism
  • Humans
  • Neoplasms* / therapy
  • Neoplastic Stem Cells / metabolism
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Biomarkers, Tumor